Source: Eur Respir J 2012; 39: 626-634
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Oxlade O., Falzon D., Menzies D.. The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis. Eur Respir J 2012; 39: 626-634

Member's Comments

No comment yet.

Related content which might interest you: Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007 Molecular surveillance of multi-drug resistant tuberculosis in Europe Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay Source: Eur Respir J 2013; 41: 1163-1171 Year: 2013 Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection Source: Eur Respir J 2010; 36: 1242-1247 Year: 2010 The problem of multi-drug resistant (MDR)-TB Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties Year: 2005 The WHO strategy for TB control and elimination Source: Eur Respir Mon 2012; 58: 242-253 Year: 2012 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Microbiology of Mycobacterium tuberculosis and a new diagnostic test for TB Source: Eur Respir Mon 2012; 58: 1-13 Year: 2012 Recent transmission of drug resistant M. tuberculosis in Latvia Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Patient choice promotes adherence in preventive treatment for latent tuberculosis Source: Eur Respir J 2007; 30: 728-735 Year: 2007 Cost-effectiveness of two latent tuberculosis infection screening strategies Source: International Congress 2018 – Current practices in and attitudes to screening for tuberculosis, and a discussion about genetic diversity Year: 2018 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 TB drug resistance in high-incidence countries Source: Eur Respir Mon 2012; 58: 95-110 Year: 2012